VNA
TXG icon

Valley National Advisers’s 10x Genomics TXG Stock Holding History

Valley National Advisers’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-90
Closed -$1K – 1129
2024
Q2 		$1K Hold
90
– – ﹤0.01% 1141
2024
Q1 		$3K Buy
90
+5
+6% +$220 ﹤0.01% 906
2023
Q4 		$4K Buy
+85
New +$3.7K ﹤0.01% 845

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Valley National Advisers's TXG Position: Q3 2024 in Review

Valley National Advisers sold out of 10x Genomics (TXG) in Q3 2024, closing a stake of 90 shares — an estimated $1K sold.

Valley National Advisers first reported a position in TXG in Q4 2023 and held it in 3 quarters. The position peaked at $4K in Q4 2023. 266 funds tracked by Wall St. Rank hold TXG as of Q3 2024.

  • Valley National Advisers reported no remaining 10x Genomics position as of Q3 2024 after selling out during the quarter.
  • Valley National Advisers sold 90 10x Genomics shares in Q3 2024, an estimated $1K.
  • Valley National Advisers first reported a position in 10x Genomics in Q4 2023 and held it in 3 quarters.
  • Valley National Advisers's 10x Genomics position peaked at $4K in Q4 2023.
  • 266 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2024.

Based on Valley National Advisers's 13F filing for Q3 2024, filed 24 Oct 2024.